Blume-Jensen Peter, President and CEO of Acrivon Therapeutics ($ACRV), made one open market purchase of shares worth $82,124 in the last year, with the most recent on January 14, 2026. This ranks him 2,572nd among nearly 5,000 insiders by purchase amount, below the average of $1.5 million across 3.3 transactions. He reported no open market sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 1, 2026 | Acrivon Therapeutics, Inc. | $ACRV | Blume-Jensen Peter | President and CEO | A | Stock Option (Right to Buy) | 417210 | $0.00 | 602,705.0000 | 38,560,464 | 224.92% | 1.08% |
| March 1, 2026 | Acrivon Therapeutics, Inc. | $ACRV | Blume-Jensen Peter | President and CEO | A | Stock Option (Right to Buy) | 185495 | $0.00 | 602,705.0000 | 38,560,464 | 44.46% | 0.48% |
| Feb. 21, 2026 | Acrivon Therapeutics, Inc. | $ACRV | Blume-Jensen Peter | President and CEO | F | Common Stock | 14265 | $1.53 | 2,394,331.0000 | 38,560,464 | 0.59% | 0.04% |
| Feb. 14, 2026 | Acrivon Therapeutics, Inc. | $ACRV | Blume-Jensen Peter | President and CEO | F | Common Stock | 1302 | $1.63 | 2,408,596.0000 | 38,560,464 | 0.05% | 0.00% |
| Feb. 14, 2026 | Acrivon Therapeutics, Inc. | $ACRV | Blume-Jensen Peter | President and CEO | F | Common Stock | 579 | $1.63 | 2,408,596.0000 | 38,560,464 | 0.02% | 0.00% |
| Jan. 14, 2026 | Acrivon Therapeutics, Inc. | $ACRV | Blume-Jensen Peter | President and CEO | P | Common Stock | 49000 | $1.68 | 2,410,477.0000 | 38,560,464 | 2.07% | 0.13% |
| Nov. 21, 2025 | Acrivon Therapeutics, Inc. | $ACRV | Blume-Jensen Peter | President and CEO | F | Common Stock | 19904 | $2.30 | 2,361,477.0000 | 38,560,464 | 0.84% | 0.05% |
| Nov. 14, 2025 | Acrivon Therapeutics, Inc. | $ACRV | Blume-Jensen Peter | President and CEO | F | Common Stock | 490 | $2.24 | 2,381,381.0000 | 38,560,464 | 0.02% | 0.00% |
| Nov. 14, 2025 | Acrivon Therapeutics, Inc. | $ACRV | Blume-Jensen Peter | President and CEO | F | Common Stock | 59765 | $2.24 | 2,381,381.0000 | 38,560,464 | 2.45% | 0.15% |
| Aug. 21, 2025 | Acrivon Therapeutics, Inc. | $ACRV | Blume-Jensen Peter | President and CEO | F | Common Stock | 19905 | $1.32 | 2,441,636.0000 | 33,791,817 | 0.81% | 0.06% |
| Aug. 14, 2025 | Acrivon Therapeutics, Inc. | $ACRV | Blume-Jensen Peter | President and CEO | F | Common Stock | 59766 | $1.39 | 2,461,541.0000 | 33,791,817 | 2.37% | 0.18% |
| Aug. 14, 2025 | Acrivon Therapeutics, Inc. | $ACRV | Blume-Jensen Peter | President and CEO | F | Common Stock | 490 | $1.39 | 2,461,541.0000 | 33,791,817 | 0.02% | 0.00% |
| May 21, 2025 | Acrivon Therapeutics, Inc. | $ACRV | Blume-Jensen Peter | President and CEO | F | Common Stock | 19904 | $1.15 | 2,521,797.0000 | 33,791,817 | 0.78% | 0.06% |
| May 14, 2025 | Acrivon Therapeutics, Inc. | $ACRV | Blume-Jensen Peter | President and CEO | F | Common Stock | 59766 | $1.14 | 2,541,701.0000 | 33,791,817 | 2.30% | 0.18% |
| May 14, 2025 | Acrivon Therapeutics, Inc. | $ACRV | Blume-Jensen Peter | President and CEO | F | Common Stock | 491 | $1.14 | 2,541,701.0000 | 33,791,817 | 0.02% | 0.00% |
| March 1, 2025 | Acrivon Therapeutics, Inc. | $ACRV | Blume-Jensen Peter | President and CEO | A | Stock Option (Right to Buy) | 390390 | $0.00 | 530,930.0000 | 33,791,817 | 277.78% | 1.16% |
| March 1, 2025 | Acrivon Therapeutics, Inc. | $ACRV | Blume-Jensen Peter | President and CEO | A | Stock Option (Right to Buy) | 140540 | $0.00 | 530,930.0000 | 33,791,817 | 36.00% | 0.42% |
| Feb. 21, 2025 | Acrivon Therapeutics, Inc. | $ACRV | Blume-Jensen Peter | President and CEO | F | Common Stock | 19904 | $5.54 | 2,601,958.0000 | 33,791,817 | 0.76% | 0.06% |
| Feb. 14, 2025 | Acrivon Therapeutics, Inc. | $ACRV | Blume-Jensen Peter | President and CEO | F | Common Stock | 37152 | $5.42 | 2,621,862.0000 | 33,791,817 | 1.40% | 0.11% |
| Feb. 14, 2025 | Acrivon Therapeutics, Inc. | $ACRV | Blume-Jensen Peter | President and CEO | F | Common Stock | 579 | $5.42 | 2,621,862.0000 | 33,791,817 | 0.02% | 0.00% |
| March 1, 2024 | Acrivon Therapeutics, Inc. | $ACRV | Blume-Jensen Peter | President and CEO | A | Stock Option (Right to Buy) | 225226 | $0.00 | 315,316.0000 | 22,078,190 | 250.00% | 1.02% |
| March 1, 2024 | Acrivon Therapeutics, Inc. | $ACRV | Blume-Jensen Peter | President and CEO | A | Stock Option (Right to Buy) | 90090 | $0.00 | 315,316.0000 | 22,078,190 | 40.00% | 0.41% |
| Nov. 21, 2024 | Acrivon Therapeutics, Inc. | $ACRV | Blume-Jensen Peter | President and CEO | F | Common Stock | 19910 | $6.44 | 2,659,593.0000 | 38,105,131 | 0.74% | 0.05% |
| Nov. 14, 2024 | Acrivon Therapeutics, Inc. | $ACRV | Blume-Jensen Peter | President and CEO | F | Common Stock | 59766 | $7.92 | 2,679,503.0000 | 38,105,131 | 2.18% | 0.16% |
| Nov. 14, 2024 | Acrivon Therapeutics, Inc. | $ACRV | Blume-Jensen Peter | President and CEO | F | Common Stock | 490 | $7.92 | 2,679,503.0000 | 38,105,131 | 0.02% | 0.00% |
| Aug. 21, 2024 | Acrivon Therapeutics, Inc. | $ACRV | Blume-Jensen Peter | President and CEO | F | Common Stock | 79616 | $9.19 | 2,739,759.0000 | 22,078,190 | 2.82% | 0.36% |
| Aug. 14, 2024 | Acrivon Therapeutics, Inc. | $ACRV | Blume-Jensen Peter | President and CEO | F | Common Stock | 59765 | $7.02 | 2,819,375.0000 | 22,078,190 | 2.08% | 0.27% |
| May 14, 2024 | Acrivon Therapeutics, Inc. | $ACRV | Blume-Jensen Peter | President and CEO | F | Common Stock | 54918 | $8.36 | 2,879,630.0000 | 22,078,190 | 1.87% | 0.25% |
| Feb. 14, 2024 | Acrivon Therapeutics, Inc. | $ACRV | Blume-Jensen Peter | President and CEO | F | Common Stock | 41861 | $3.40 | 2,935,038.0000 | 22,078,190 | 1.41% | 0.19% |
| Nov. 14, 2023 | Acrivon Therapeutics, Inc. | $ACRV | Blume-Jensen Peter | President and CEO | F | Common Stock | 239023 | $5.08 | 2,977,478.0000 | 0 | 7.43% | 0.00% |
| Aug. 21, 2023 | Acrivon Therapeutics, Inc. | $ACRV | Blume-Jensen Peter | President and CEO | A | Common Stock | 493994 | $0.00 | 3,218,401.0000 | 0 | 18.13% | 0.00% |
| May 31, 2023 | Acrivon Therapeutics, Inc. | $ACRV | Blume-Jensen Peter | President and CEO | M | Stock Option (Right to Buy) | 33605 | $0.00 | 153,085.0000 | 0 | 18.00% | 0.00% |
| May 31, 2023 | Acrivon Therapeutics, Inc. | $ACRV | Blume-Jensen Peter | President and CEO | M | Common Stock | 33605 | $3.88 | 2,724,407.0000 | 0 | 1.25% | 0.00% |